Navidea prevails in litigation with lender; shares ahead 10% [Seeking Alpha]
Navidea Biopharmaceuticals, Inc. (NAVB)
NASDAQ:AMEX Investor Relations:
ir.navidea.com
Company Research
Source: Seeking Alpha
Navidea prevails in litigation with lender; shares ahead 10% Navidea Biopharmaceuticals ( NAVB +9.5% announcement The court ruled that CRG collected excess remedies over and above $66.0M and must pay NAVB ~$4.3M plus interest. The dispute arose in May 2016 with CRG notified
Show less
Read more
Impact Snapshot
Event Time:
NAVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAVB alerts
High impacting Navidea Biopharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NAVB
News
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat